Vinorelbine Alters lncRNA Expression in Association with EGFR Mutational Status and Potentiates Tumor Progression Depending on NSCLC Cell Lines’ Genetic Profile
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) as the most common type. In addition, NSCLC has a high mortality rate and an overall adverse patient outcome. Although significant improvements have been made in therapeutic options,...
Main Authors: | Hasan Alsharoh, Paul Chiroi, Andreea Nutu, Lajos Raduly, Oana Zanoaga, Ioana Berindan-Neagoe |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/12/3298 |
Similar Items
-
Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, et al.
Published: (2022-01-01) -
Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
by: Jinyao Zhang, et al.
Published: (2021-12-01) -
Vinorelbine as First-Line Treatment in Stage IV Canine Primary Pulmonary Carcinoma
by: Valentina Rinaldi, et al.
Published: (2023-11-01) -
Combined Chemotherapy with Vinorelbine and Ifosfamide as Third-line Treatment and Beyond of Advanced Non-small Cell Lung Cancer
by: Yang ZHOU, et al.
Published: (2015-06-01) -
LncRNAs and EGFRvIII sequestered in TEPs enable blood-based NSCLC diagnosis
by: Luo CL, et al.
Published: (2018-06-01)